The major factors for the growth of North American breast cancer screening tests market are the rising incidence of breast cancer, increasing government initiatives and support, and technological advancements.

Breast cancer is currently the leading cause of cancer-related deaths in women in North America. According to the American Cancer Society, in 2017, an estimated 252,710 new cases of invasive breast cancer were diagnosed among women. In addition, 63,410 cases of in situ breast carcinoma were diagnosed among women. Approximately 40,610 women and 460 men died from breast cancer in 2017, and the number of breast cancer cases is expected to increase in the coming years. It is estimated that the risk of an individual dying from breast cancer may increase in the coming years. Hence, the increase in the prevalence of breast cancer is a major factor contributing to the revenue growth of the market. Thus, owing to the above-mentioned factors, the market is expected to witness high growth over the forecast period.

Key Market Trends

Mammogram under the Imaging Test Segment is Expected to Hold the Largest Market Share

Mammograms are used in most cases of breast cancer screening. The United States Preventive Services Task ForceExternal (USPSTF) recommends that women aged between 50 and 74 years old and are at average risk for breast cancer should get a mammogram every two years. Furthermore, mammograms are the best way to find breast cancer early, and having regular mammograms can lower the risk of dying from breast cancer. Currently, a mammogram is the best way to find breast cancer in women. However, mammography is less likely to find breast tumors in women with dense breast tissue, as both tumors and dense breast tissues appear white on a mammogram, making it harder to find a tumor in such cases. Thus, there are other imaging techniques that are also likely to gain more popularity over the forecast period. Owing to the rising cases of breast cancer in the region, the market is expected to witness high growth over the forecast period.

Competitive Landscape

The market studied is moderately fragmented in nature, owing to the presence of several small and major market players. Some of the market players are Agendia BV, Fujifilm Holdings Corporation, Hologic Inc., Metabolomic Technologies Inc., Myriad Genetics, QIAGEN NV, Quest Diagnostics Incorporated, and Siemens Healthineers, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support